# Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment

> **NCT01239459** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** Teriflunomide HMR1726
- **DRUG:** Cholestyramine

## Key facts

- **NCT ID:** NCT01239459
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-02
- **Final completion:** 2011-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2012-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239459, "Pharmacokinetic and Tolerability Study of 14 mg Single Dose of Teriflunomide in Subjects With Severe Renal Impairment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01239459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*